Numerous research studies have focused on investigating the effects of circulating resistin levels on CRC risk, progression, metastasis, invasion, tumor angiogenesis, and chemotherapy efficacy in CRC patients [20-22]. The gene discussed is RETN; the disease is neoplasm.